Showing results (51-60 of 291) with videos related to
Sort By:
Pageof 30
Arzneimittel-Forschung|December 1, 1988
Coronary vascular activity of the novel inotropic pro-drug ibopamine and the de-esterified active form epinineE H Ohlstein, G A Kopia, R R RuffoloEuropean Journal of Pharmacology|December 3, 1985
The DA1 receptor agonist fenoldopam (SK & F 82526) is also an alpha 2-adrenoceptor antagonistE H Ohlstein, B Zabko-Potapovich, B A BerkowitzCurrent Opinion in Chemical Biology|July 27, 1999
Apoptosis: a potential target for discovering novel therapies for cardiovascular diseasesT L Yue, E H Ohlstein, R R RuffoloAnnual Review of Pharmacology and Toxicology|June 3, 2000
Drug discovery in the next millenniumE H Ohlstein, R R Ruffolo, J D ElliottBritish Journal of Pharmacology|March 1, 1990
The effect of diltiazem on the coronary haemodynamic and cardiac functional effects produced by intracoronary administration of endothelin-1 in the anaesthetized dogA J Nichols, P F Koster, E H OhlsteinEuropean Journal of Pharmacology|September 5, 1995
Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin AT1 receptor antagonistN Aiyar, E Baker, L Vickery-Clark, et al.Proceedings of the National Academy of Sciences of the United States of America|August 16, 1994
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonistE H Ohlstein, P Nambi, S A Douglas, et al.The American Journal of Physiology|December 1, 1990
Vasodilation induced by endothelin: role of EDRF and prostanoids in rat hindquartersE H Ohlstein, L Vickery, C Sauermelch, et al.Journal of Hypertension|May 1, 1994
BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertensionS A Douglas, M Gellai, M Ezekiel, et al.British Journal of Pharmacology|February 1, 1993
Endothelin-1 does not mediate hypoxic vasoconstriction in canine isolated blood vessels: effect of BQ-123S A Douglas, L M Vickery-Clark, E H OhlsteinPageof 30